BERGENBIO COMPLETES RECRUITMENT OF PHASE II AML STUDY (BGBC003)
Bergen, Norway, 7 September 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce the completion of patient recruitment into BGBC003 (ClinicalTrials.gov ID: NCT02488408), a Phase Ib/II multicenter open-label study of bemcentinib as a single agent and in combination with cytarabine or decitabine in patients with Acute Myeloid Leukemia (AML) or as a single agent in patients with myelodysplastic syndrome (MDS). BerGenBio has recruited a total of 86 patients in